Phase 1 Kidney Cancer Trial, Recruiting NCT06595329 Sponsor: University Hospital of Split Condition: Kidney Cancer
Back to Kidney Cancer

Phase 1 Kidney Cancer Trial, Recruiting

NCT06595329
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who are scheduled to have surgery to fully or partially remove a kidney because of kidney cancer.
  • People who are considered to be in reasonably good to moderate overall health before surgery, based on a standard medical assessment (known as ASA class I–III — confirm with trial site if unsure which category applies to you).

Who may not be able to join:

  • People who do not want to take part in the study.
  • People whose body weight relative to their height (BMI) is either very high (above 35) or very low (below 15).
  • People with severely reduced kidney function, serious liver disease, or severe heart failure.
  • People who are considered to be in poor overall health before surgery (ASA class IV or higher — confirm with trial site).
  • People who have allergies to certain anaesthetic medicines used in this study, blood clotting problems, or a skin infection at the area where an injection would be given.
  • People who are currently dependent on strong pain-relief medicines (opioids).
  • People who are unable to communicate before surgery due to severe memory loss, a language barrier, or a mental health or neurological condition.
  • People for whom the planned procedures in this study cannot be carried out for technical reasons (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Svjetlana Došenović, MD Phd, UH Split

Phone: +385955234851

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
University Hospital of Split
Registry
ClinicalTrials.gov
Start date
15 January 2025
Est. completion
15 October 2025

Where this trial is recruiting

🇭🇷 Croatia

Primary endpoints

NRS score at 24 hours postoperatively

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov